Nisa Investment Advisors LLC Has $114,000 Holdings in Revolution Medicines, Inc. (NASDAQ:RVMD)

Nisa Investment Advisors LLC trimmed its holdings in shares of Revolution Medicines, Inc. (NASDAQ:RVMD) by 13.7% during the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 3,210 shares of the company’s stock after selling 508 shares during the quarter. Nisa Investment Advisors LLC’s holdings in Revolution Medicines were worth $114,000 at the end of the most recent quarter.

A number of other hedge funds have also made changes to their positions in the stock. China Universal Asset Management Co. Ltd. lifted its holdings in Revolution Medicines by 45.1% in the 1st quarter. China Universal Asset Management Co. Ltd. now owns 89,962 shares of the company’s stock worth $3,181,000 after purchasing an additional 27,982 shares during the last quarter. Bank of New York Mellon Corp raised its position in shares of Revolution Medicines by 2.4% in the first quarter. Bank of New York Mellon Corp now owns 582,721 shares of the company’s stock valued at $20,605,000 after purchasing an additional 13,706 shares during the period. GF Fund Management CO. LTD. lifted its stake in shares of Revolution Medicines by 21.9% in the first quarter. GF Fund Management CO. LTD. now owns 4,307 shares of the company’s stock worth $152,000 after buying an additional 775 shares during the last quarter. Principal Financial Group Inc. lifted its stake in shares of Revolution Medicines by 2.1% in the first quarter. Principal Financial Group Inc. now owns 12,792 shares of the company’s stock worth $452,000 after buying an additional 259 shares during the last quarter. Finally, Teacher Retirement System of Texas boosted its holdings in shares of Revolution Medicines by 11.0% during the 1st quarter. Teacher Retirement System of Texas now owns 38,426 shares of the company’s stock worth $1,359,000 after buying an additional 3,794 shares during the period. Institutional investors and hedge funds own 94.34% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research analysts recently commented on the stock. Guggenheim reiterated a “buy” rating and issued a $80.00 target price on shares of Revolution Medicines in a report on Wednesday, June 25th. HC Wainwright reissued a “buy” rating and set a $72.00 price objective (down previously from $73.00) on shares of Revolution Medicines in a research report on Wednesday, May 14th. Needham & Company LLC reaffirmed a “buy” rating and issued a $57.00 target price on shares of Revolution Medicines in a report on Tuesday, June 24th. Wedbush reaffirmed an “outperform” rating and issued a $73.00 price target (up from $67.00) on shares of Revolution Medicines in a research report on Tuesday, June 24th. Finally, Oppenheimer upped their price target on Revolution Medicines from $70.00 to $75.00 and gave the stock an “outperform” rating in a report on Thursday, May 8th. Eleven equities research analysts have rated the stock with a buy rating, According to MarketBeat.com, Revolution Medicines presently has a consensus rating of “Buy” and a consensus target price of $68.91.

Revolution Medicines Stock Down 1.9%

Revolution Medicines stock opened at $38.30 on Friday. The business has a 50 day moving average price of $39.11 and a two-hundred day moving average price of $39.30. Revolution Medicines, Inc. has a 12 month low of $29.17 and a 12 month high of $62.40. The stock has a market cap of $7.13 billion, a price-to-earnings ratio of -9.58 and a beta of 1.06.

Revolution Medicines (NASDAQ:RVMD) last released its quarterly earnings data on Wednesday, May 7th. The company reported ($1.13) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.12) by ($0.01). During the same quarter last year, the company posted ($0.70) earnings per share. On average, analysts expect that Revolution Medicines, Inc. will post -3.49 earnings per share for the current fiscal year.

Revolution Medicines Company Profile

Revolution Medicines, Inc, a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company’s research and development pipeline comprises RAS(ON) inhibitors designed to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors for combination treatment strategies.